FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Secukinumab Retention Rates Studied in Psoriasis Patients with or Without GLP-1 RA Co-Therapy
研究ライブラリに戻る

Secukinumab Retention Rates Studied in Psoriasis Patients with or Without GLP-1 RA Co-Therapy

November 20, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

Secukinumab Retention Rates Studied in Psoriasis Patients with or Without GLP-1 RA Co-Therapy

A new real-world study, registered on ClinicalTrials.gov (NCT07881783), is investigating the long-term effectiveness and adherence of secukinumab treatment for moderate-to-severe plaque psoriasis. The research aims to determine if combining secukinumab with glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy maintains non-inferior retention rates compared to using secukinumab alone over a period of 12 months.

The study, sponsored by Novartis Pharmaceuticals, is currently active but not recruiting participants. This research is crucial for understanding how the addition of GLP-1 RA affects treatment adherence and long-term outcomes in patients with psoriasis who are already on secukinumab therapy.

Background

Psoriasis is a chronic autoimmune condition that causes red, itchy, scaly patches to appear on the skin. Secukinumab, an interleukin-17A (IL-17A) inhibitor, has been widely used as a biologic treatment for moderate-to-severe psoriasis. However, long-term adherence and retention rates of secukinumab therapy have been variable, with some patients discontinuing due to side effects or lack of efficacy.

The addition of GLP-1 RAs, which are typically used in diabetes management, has shown promise in improving metabolic health and potentially enhancing the therapeutic response in psoriasis. This study seeks to explore whether combining these two treatments can improve patient outcomes without compromising adherence rates.

Key Details

Researchers will monitor treatment retention over a 12-month period for patients who receive secukinumab either alone or in combination with GLP-1 RA therapy. The primary objective is to determine if the combined approach does not result in inferior retention compared to monotherapy use of secukinumab.

Secondary objectives include evaluating adherence patterns, long-term treatment retention, and healthcare resource utilization across both study groups. This comprehensive assessment will provide valuable insights into how adding GLP-1 RA influences patient management strategies for psoriasis.

Key Takeaways

  • Non-Inferior Retention: The study aims to confirm that the addition of GLP-1 RA does not reduce retention rates of secukinumab.
  • Adherence Patterns: Researchers will analyze adherence behaviors in patients using both therapies versus those on secukinumab alone.
  • Healthcare Utilization: Data collected will help understand how combined therapy impacts overall healthcare resource use by psoriasis patients.
  • Long-Term Outcomes: The study provides a basis for evaluating the long-term efficacy and safety of combining these treatments.

What This Means

For the peptide community, this research highlights the potential benefits of multi-modal therapeutic approaches in managing chronic conditions like psoriasis. By examining how GLP-1 RA impacts secukinumab treatment retention and adherence, clinicians may be better equipped to tailor personalized care plans that enhance patient outcomes while minimizing side effects.

Moreover, understanding these interactions can pave the way for future studies exploring synergistic effects between different biologics and metabolic agents in treating autoimmune diseases. This could lead to more effective management strategies and improved quality of life for patients suffering from psoriasis and related conditions.

---

Source: ClinicalTrials.gov — Published 2026-11-20

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。